PFIZER INC (PFE) Free cash flow
- Free cash flow · 12 months (USD): Value $10.98B; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-28..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-28..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-28..
- Free cash flow margin · 12 months: Value 17.25%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-28..
Free cash flow
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $10.98B | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-28. $13.40B − $2.42B ≈ $10.98B |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 17.25% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-28. $10.98B ÷ $63.70B × 100 ≈ 17.25% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $13.40B | Cash generated by operating activities. Period ending 2026-06-28. |
| Operating cash flow / net income · 12 months | 3.09× | Operating cash flow / net income. Period ending 2026-06-28. $13.40B ÷ $4.33B ≈ 3.09× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 13.40B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 2.42B USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 10.98B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 63.70B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | |
| Net income | 4.33B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | $10.98B | (m) | $13.40B | $2.42B | (m) | $63.70B | (m) | $4.33B | (m) | (m) | 17.25% | 3.09× |
| 2026-03-29 | $9.48B | (m) | $11.98B | $2.50B | (m) | $63.31B | (m) | $7.49B | (m) | (m) | 14.98% | 1.60× |
| 2025-12-31 | $9.07B | (m) | $11.70B | $2.63B | (m) | $62.58B | (m) | $7.77B | (m) | (m) | 14.50% | 1.51× |
| 2025-09-28 | $10.38B | (m) | $13.08B | $2.70B | (m) | $62.78B | (m) | $9.83B | (m) | (m) | 16.53% | 1.33× |
| 2025-06-29 | $12.44B | (m) | $15.19B | $2.75B | (m) | $63.83B | (m) | $10.75B | (m) | (m) | 19.49% | 1.41× |
| 2025-03-30 | $11.22B | (m) | $13.99B | $2.77B | (m) | $62.46B | (m) | $7.88B | (m) | (m) | 17.96% | 1.77× |
| 2024-12-31 | $9.84B | (m) | $12.74B | $2.91B | (m) | $63.63B | (m) | $8.03B | (m) | (m) | 15.46% | 1.59× |
| 2024-09-29 | $8.23B | (m) | $11.26B | $3.04B | (m) | $51.79B | (m) | $4.25B | (m) | (m) | 15.88% | 2.65× |
| 2024-06-30 | $4.81B | (m) | $8.01B | $3.19B | (m) | $47.58B | (m) | $-2.60B | (m) | (m) | 10.11% | -3.08× |
| 2024-03-31 | $5.11B | (m) | $8.58B | $3.47B | (m) | $47.31B | (m) | $-309.00M | (m) | (m) | 10.79% | -27.76× |
| 2023-12-31 | $4.79B | (m) | $8.70B | $3.91B | (m) | $50.91B | (m) | $2.12B | (m) | (m) | 9.41% | 4.11× |
| 2023-10-01 | $8.18B | (m) | $12.04B | $3.86B | (m) | $68.54B | (m) | $10.48B | (m) | (m) | 11.93% | 1.15× |
| 2023-07-02 | $10.66B | (m) | $14.56B | $3.90B | (m) | $77.94B | (m) | $21.47B | (m) | (m) | 13.68% | 0.68× |
| 2023-04-02 | $20.21B | (m) | $23.94B | $3.73B | (m) | $92.95B | (m) | $29.05B | (m) | (m) | 21.74% | 0.82× |
| 2022-12-31 | $26.03B | (m) | $29.27B | $3.24B | (m) | $100.33B | (m) | $31.37B | (m) | (m) | 25.95% | 0.93× |
| 2022-10-02 | $23.36B | (m) | $26.60B | $3.24B | (m) | $99.88B | (m) | $29.77B | (m) | (m) | 23.39% | 0.89× |
| 2022-07-03 | $28.44B | (m) | $31.45B | $3.01B | (m) | $101.28B | (m) | $29.31B | (m) | (m) | 28.08% | 1.07× |
| 2022-04-03 | $31.78B | (m) | $34.58B | $2.80B | (m) | $92.43B | (m) | $24.97B | (m) | (m) | 34.38% | 1.39× |
| 2021-12-31 | $29.87B | (m) | $32.58B | $2.71B | (m) | $81.29B | (m) | $21.98B | (m) | (m) | 36.74% | 1.48× |
| 2021-10-03 | $29.73B | (m) | $32.29B | $2.56B | (m) | $69.34B | (m) | $19.89B | (m) | (m) | 42.88% | 1.62× |
| 2021-07-04 | $21.11B | (m) | $23.55B | $2.44B | (m) | $55.52B | (m) | $13.21B | (m) | (m) | 38.03% | 1.78× |
| 2021-04-04 | $13.45B | (m) | $15.81B | $2.36B | (m) | $46.41B | (m) | $11.14B | (m) | (m) | 28.98% | 1.42× |
| 2020-12-31 | $12.15B | (m) | $14.40B | $2.25B | (m) | $41.91B | (m) | $9.62B | (m) | (m) | 28.99% | 1.50× |
| 2020-09-27 | $10.41B | (m) | $12.55B | $2.14B | (m) | $48.65B | (m) | $8.69B | (m) | (m) | 21.39% | 1.44× |
| 2020-06-28 | $12.79B | (m) | $14.97B | $2.18B | (m) | $49.20B | (m) | $14.17B | (m) | (m) | 25.99% | 1.06× |
| 2020-03-29 | $11.84B | (m) | $14.02B | $2.18B | (m) | $50.66B | (m) | $15.79B | (m) | (m) | 23.38% | 0.89× |
| 2019-12-31 | $10.41B | (m) | $12.59B | $2.18B | (m) | $51.75B | (m) | $16.27B | (m) | (m) | 20.12% | 0.77× |
| 2019-09-29 | $11.37B | (m) | $13.56B | $2.19B | (m) | $53.04B | (m) | $16.22B | (m) | (m) | 21.43% | 0.84× |
| 2019-06-30 | $12.13B | (m) | $14.31B | $2.17B | (m) | $53.66B | (m) | $12.65B | (m) | (m) | 22.62% | 1.13× |
| 2019-03-31 | $13.43B | (m) | $15.54B | $2.12B | (m) | $53.86B | (m) | $11.48B | (m) | (m) | 24.93% | 1.35× |
| 2018-12-31 | $13.79B | (m) | $15.83B | $2.04B | (m) | $53.65B | (m) | $11.15B | (m) | (m) | 25.70% | 1.42× |
| 2018-09-30 | $15.79B | (m) | $17.85B | $2.06B | (m) | (m) | (m) | $23.82B | (m) | (m) | (m) | 0.75× |
| 2018-07-01 | $15.52B | (m) | $17.48B | $1.96B | (m) | (m) | (m) | $22.55B | (m) | (m) | (m) | 0.78× |
| 2018-04-01 | $14.88B | (m) | $16.87B | $1.98B | (m) | (m) | (m) | $21.75B | (m) | (m) | (m) | 0.78× |
| 2017-12-31 | $14.51B | (m) | $16.47B | $1.96B | (m) | (m) | (m) | $21.31B | (m) | (m) | (m) | 0.77× |
| 2017-10-01 | $13.53B | (m) | $15.48B | $1.95B | (m) | (m) | (m) | $9.81B | (m) | (m) | (m) | 1.58× |
| 2017-07-02 | $13.40B | (m) | $15.33B | $1.93B | (m) | (m) | (m) | $8.32B | (m) | (m) | (m) | 1.84× |
| 2017-04-02 | $13.80B | (m) | $15.68B | $1.88B | (m) | (m) | (m) | $7.30B | (m) | (m) | (m) | 2.15× |
| 2016-12-31 | $14.08B | (m) | $15.90B | $1.82B | (m) | (m) | (m) | $7.21B | (m) | (m) | (m) | 2.20× |
| 2016-10-02 | $12.91B | (m) | $14.65B | $1.75B | (m) | (m) | (m) | $6.18B | (m) | (m) | (m) | 2.37× |
| 2016-07-03 | $13.37B | (m) | $14.97B | $1.60B | (m) | (m) | (m) | $6.99B | (m) | (m) | (m) | 2.14× |
| 2016-04-03 | $14.02B | (m) | $15.48B | $1.46B | (m) | (m) | (m) | $7.60B | (m) | (m) | (m) | 2.04× |
| 2015-12-31 | $13.12B | (m) | $14.51B | $1.40B | (m) | (m) | (m) | $6.96B | (m) | (m) | (m) | 2.09× |
| 2015-09-27 | $14.06B | (m) | $15.20B | $1.14B | (m) | (m) | (m) | $8.36B | (m) | (m) | (m) | 1.82× |
| 2015-06-28 | $13.51B | (m) | $14.64B | $1.13B | (m) | (m) | (m) | $8.90B | (m) | (m) | (m) | 1.65× |
| 2015-03-29 | $13.49B | (m) | $14.63B | $1.15B | (m) | (m) | (m) | $9.18B | (m) | (m) | (m) | 1.59× |
| 2014-12-31 | $15.68B | (m) | $16.88B | $1.20B | (m) | (m) | (m) | $9.13B | (m) | (m) | (m) | 1.85× |
| 2014-09-28 | $16.03B | (m) | $17.29B | $1.26B | (m) | (m) | (m) | $10.47B | (m) | (m) | (m) | 1.65× |
| 2014-06-29 | $17.46B | (m) | $18.73B | $1.26B | (m) | $50.33B | (m) | $10.40B | (m) | (m) | 34.70% | 1.80× |
| 2014-03-30 | $17.10B | (m) | $18.40B | $1.30B | (m) | $50.53B | (m) | $21.58B | (m) | (m) | 33.85% | 0.85× |
| 2013-12-31 | $16.56B | (m) | $17.77B | $1.21B | (m) | $51.58B | (m) | $22.00B | (m) | (m) | 32.10% | 0.81× |
| 2013-09-29 | $15.95B | (m) | $17.23B | $1.28B | (m) | $56.25B | (m) | $25.75B | (m) | (m) | 28.36% | 0.67× |
| 2013-06-30 | $15.04B | (m) | $16.33B | $1.29B | (m) | $56.56B | (m) | $26.37B | (m) | (m) | 26.59% | 0.62× |
| 2013-03-31 | $15.25B | (m) | $16.52B | $1.27B | (m) | $57.60B | (m) | $15.53B | (m) | (m) | 26.47% | 1.06× |
| 2012-12-31 | $15.73B | (m) | $17.05B | $1.33B | (m) | $58.99B | (m) | $14.57B | (m) | (m) | 26.66% | 1.17× |
| 2012-09-30 | $15.63B | (m) | $17.06B | $1.43B | (m) | $62.23B | (m) | $9.69B | (m) | (m) | 25.12% | 1.76× |
| 2012-07-01 | $14.89B | (m) | $16.50B | $1.60B | (m) | $64.86B | (m) | $10.22B | (m) | (m) | 22.97% | 1.61× |
| 2012-04-01 | $16.71B | (m) | $18.37B | $1.66B | (m) | $66.33B | (m) | $9.58B | (m) | (m) | 25.19% | 1.92× |
| 2011-12-31 | $18.58B | (m) | $20.24B | $1.66B | (m) | $67.42B | (m) | $10.01B | (m) | (m) | 27.56% | 2.02× |
| 2011-10-02 | $19.63B | (m) | $21.24B | $1.61B | (m) | $68.24B | (m) | $11.46B | (m) | (m) | 28.76% | 1.85× |
| 2011-07-03 | $22.04B | (m) | $23.48B | $1.44B | (m) | $67.22B | (m) | $8.59B | (m) | (m) | 32.79% | 2.73× |
| 2011-04-03 | $21.00B | (m) | $22.46B | $1.46B | (m) | $67.73B | (m) | $8.45B | (m) | (m) | 31.00% | 2.66× |
| 2010-12-31 | $9.94B | (m) | $11.45B | $1.51B | (m) | $67.81B | (m) | $8.26B | (m) | (m) | 14.66% | 1.39× |
| 2010-10-03 | $8.63B | (m) | $10.02B | $1.39B | (m) | $66.78B | (m) | $6.13B | (m) | (m) | 12.93% | 1.63× |
| 2010-07-04 | $6.08B | (m) | $7.44B | $1.36B | (m) | $62.23B | (m) | $8.15B | (m) | (m) | 9.77% | 0.91× |
| 2010-04-04 | $5.82B | (m) | $7.08B | $1.26B | (m) | $55.89B | (m) | $7.93B | (m) | (m) | 10.42% | 0.89× |
| 2009-12-31 | $15.38B | (m) | $16.59B | $1.21B | (m) | $50.01B | (m) | $8.63B | (m) | (m) | 30.76% | 1.92× |
| 2009-09-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $16.54B | (m) | $18.24B | $1.70B | (m) | $48.30B | (m) | $8.10B | (m) | (m) | 34.24% | 2.25× |
| 2008-09-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $11.47B | (m) | $13.35B | $1.88B | (m) | $48.42B | (m) | $8.14B | (m) | (m) | 23.70% | 1.64× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |